ScreenerHero

KODKodiak Sciences, Inc.

NAS · US · Healthcare · Biotechnology · kodiak.com
38.33USD-4.34%Mkt Cap: 2.41B $P/E: —

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.41B $
Enterprise Value2.43B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-229.97M $
Revenue/Share—
Last Price38.33 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS50015M1099
Valuation
P/E (Trailing)—
P/E (Forward)-11.24
PEG—
EV/EBITDA-10.50
EV/Revenue—
P/S—
P/B40.90
EPS (TTM)-4.17
EPS (Forward)-3.55
52W Range
8.29076% of range47.84
52W High47.84 USD
52W Low8.290 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-146.12%
ROA-65.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-136.01M $
CapEx (TTM)506.00K $
FCF Margin—
FCF Yield-2.42%
Net Debt-73.15M $
Net Debt/EBITDA0.32
Balance Sheet
Debt/Equity0.38
Current Ratio2.49
Quick Ratio2.39
Book Value/Sh0.9740 USD
Cash/Share2.007 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)69.00 USD
Upside (mean)+80.0%
Target Range56.00 USD – 85.00 USD
$56.00+80.0% to mean$85.00
# Analysts5
Ownership
Shares Out.62.85M
Float39.56M
Insiders5.16%
Institutions102.38%
Short Interest
Short Ratio15.4d
Short % Float25.93%
Short % Out.16.35%
Shares Short10.23M
Short (prev mo.)10.63M
Technical
SMA 5039.63 (-3.3%)
SMA 20032.09 (+19.4%)
Beta2.21
S&P 52W Chg18.16%
Avg Vol (30d)575.67K
Avg Vol (10d)584.40K
Technical Indicators
RSI (14)42.3
MACD0.0960
MACD Signal0.7182
MACD Hist.-0.6222
BB Upper45.48 USD
BB Middle41.77 USD
BB Lower38.06 USD
BB Width17.75%
ATR (14)3.015 USD
Vol Ratio (20d)0.91x